Agenda

Friday, March 8, 2019

 Agenda for ISLAA 2019
Session I – LAA Exclusion Anatomy and Imaging

7:45 AM – 7:50 AM

Welcome – Course Directors

7:50 AM – 8:00 AM

Understanding the LAA Anatomy – Relevance to Systemic Thromboembolization and Exclusion Techniques – 

8:00 AM – 8:10 AM

Pre and Intra-procedural TEE Imaging for Effective LAA Exclusion – 

8:10 AM – 8:20 AM

CT Imaging for LAA Exclusion – Pre and Post Procedural Assessment – 

8:20 AM – 8:30 AM

Left Atrial Appendage Role in Atrial Arrhythmia’s Origin and Maintenance

8:30 AM – 8:50 AM

Panel Discussion

Session II – Live Case 1

8:50  AM – 9:50 AM

Live Case – 

9:50 AM – 10:00 AM

Post-Implant Anticoagulation – Prevention, Implications and Management

10:00 AM – 10:10 AM

WATCHMAN Leaks – Prevention, Implications and Management – 

10:10 AM – 10:20 AM

Five Year Follow Up Data on Watchman Trials

10:20 AM – 10:40 AM

Panel Discussion

10:40 AM – 10:55 AM

Break

Session III – Live Case 2

10:55 AM – 11:05 AM

Tips and Tricks for Safe Epicardial Access – Micropuncture, EPiEP and More – 

11:05 AM – 12:00 PM

Live Case – 

12:00 PM – 12:10 PM

Managing Post Procedural Pericardial Drain and Pericarditis – 

12:10 PM- 12:30 PM

Panel Discussion

12:30 PM- 1:00 PM

Lunch

Session IV – 

1:00 PM – 1:10 PM

Tips and Tricks for Safe Transseptal Puncture and Device Manipulation – 

1:10 PM – 2:10 PM

Live Case – 

2:10 PM – 2:20 PM

How to Prevent and Manage Device Embolization

2:20 PM – 2:30 PM

Managing Pericardial Effusions, Onsite Thrombus, and Device Erosion in Endocardial Occluder Cases

2:30 PM  – 2:50 PM

Panel Discussion

Session V – WATCHMAN

2:50 PM – 3:00 PM

LAA Reservoir Function and Impact of Exclusion Versus Occlusion

3:00 PM – 3:10 PM

Impact of LAA Exclusion – ANP, RAAS, and LAA Homeostasis

3:10 PM – 3:30 PM

Break

3:30 PM – 4:30 PM

Live  Case –

4:10 PM – 4:20 PM

Impact on ANP, RAAS, Reservoir Functin and All – Dr. Andrea Natale

4:30 – 4:40

LAA Exclusion in Arrhythmia Treatment – LAALA AF, aMAZE and More – 

4:40 PM – 5:00 PM

Panel Discussion

Session VI – Interesting Cases

5:00 PM – 5:30 PM

What Would You Do? Most Challenging LAA Closure Cases – 

Adjourn

Saturday, March 9, 2019

 
 
 
Session VII  – 

8:00 AM – 8:20 AM

Same Day LAAO and TAVR – 

8:20 AM  – 8:30 AM

Managing Post Procedural Anticoagulation and Antiplatelet Treatment – Differences Between Devices and Patient Substrates – 

8:30 AM  – 8:40 AM

Understanding  Leaks, Pulmonary Vein and Mitral Valve Impingement in Amulet – 

8:40 AM  – 9:00 AM

Panel Discussion

Session VIII  – 

9:00 AM – 9:10 AM

Anatomic Considerations for AtriClip – Mini-Thoracotomy/VATS/Open Approach – 

9:10 AM – 9:30 AM

Recorded Case – AtriClip – 

9:30 AM – 9:40 AM

Post Procedural Management of AtriClip – Pericarditis/Anticoagulation/Imaging – 

9:40 AM  – 10:00 AM

Panel Discussion

10:00 AM – 10:20 AM

Break

Session IV Miscellaneous LAA Occlusion Devices

10:20 AM – 10:30 AM

Recorded Case – LAmbre – 

10:30 AM – 10:40 AM

LAmbre Device Data – 

10:30 AM – 10:40 AM

Less Studied LAA Occlusion Devices – An Overview and Relevance (Includes Aegis/Occlutech/Prolipsis/Cardia/Acoredis and More)

10:50 AM – 11:00 AM

Topic to be Announced

11:00 AM – 11:20 AM

Panel Discussion

 

Session X 

11:20 AM – 11:30 AM

WATCHMAN Trials Update – 

11:30 AM – 11:40 AM

Left Atrial Appendage Occlusion in Contraindicated Patients –  

11:40 AM – 11:50 AM

Amplatzer Cardiac Plug Trials Update – Amulet IDE and More – 

11:50 AM – 12:00 PM

AtriClip and Other Surgical Tools – LAAOs III and More – 

12:00 PM – 12:10 PM

WaveCrest Device Trials Update – 

12:10 PM – 12:30 PM

Panel Discussion

12:30 PM- 1:00 PM

Lunch

Session XI Oral Anticoagulants in 2017

1:00 PM – 1:30 PM

LAA Exclusion is a Better Strategy for Stroke Prophylaxis than Oral Anticoagulation in AF Patients — Debate – 

1:30 PM- 1:40 PM

Subclinical Atrial Fibrillation and Stroke – 

1:40 PM- 1:50 PM

What Other Data is Needed in the LAA Space – 

1:50 PM – 2:00 PM

Transitioning LA Exclusion Technology from Clinical Trials to Market Place – Lessons Learned from the Lariat, WATCHMAN and ACP Experience – 

2:00 PM- 2:10 PM

How to Build a Successful LAA Referral Program – 

2:10 PM- 2:30 PM

Panel Discussion

2:30 PM – 2:40 PM

Break

Session XII P

2:40 PM – 2:50 PM

Updates on the NOAC Quartet – Dabigatran, Rivaroxaban, and Edoxaban

2:50 PM – 3:00 PM

Are NOACs Really Superior to Warfarin? The Impact of Compliance and Real-World Issues – 

3:00 PM – 3:10 PM

Will NOACs Alleviate the Need for LAA Occlusion? What Will a NOAC versus LAAO Trial Look Like? – 

3:10 PM – 3:20 PM

Understanding NOACs in the 21st Century – Dual/Triple Therapy and Balancing AF and CAD – 

3:20 PM – 3:30 PM

My Patient Has an LAA Occluder and Had an Embolic CVA with No Evidence of Device Related Thrombus or Carotid Disease – 

3:30 PM – 3:40 PM

Topic to Be Announced

3:40 PM – 4:00 PM

Panel Discussion

Session XIII 

4:00 PM – 5:00 PM

Interesting Cases

5:00 PM

Adjourn/Remarks

 

Copyright © ISLAA-KC. All Rights Reserved. Privacy Policy
Site Created by KC Web Specialists, LLC.